Retrospective Study to Evaluate Efficacy and Safety of Trabectedin (Yondelis) in Sarcoma Patients
Latest Information Update: 19 Nov 2021
At a glance
- Drugs Trabectedin (Primary)
- Indications Bone cancer; Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms ReTraSarc
- 05 Nov 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Interim results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 18 Nov 2019 According to a PharmaMar media release, interim data from this trial were presented at the International Congress of the Connective Tissue Oncological Society (CTOS) 2019.